Abdominal aBscess Catheter Sclerotherapy (ABCS)

Conditions

• Abdominal Abscess

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Catheter Sclerotherapy — DRUG
  Place a drainage catheter of minimum 14F in caliber and obtain an antimicrobial sample. Saline lavage will be performed by irrigating the abscess and aspirating the contents until the character of the instilled and aspirated fluid are similar. Following this step the cavity will be drained in full and a volume of approximately equal to the cavity of povidone iodine or ethanol will be instilled through the catheter with the catheter turned off to drainage. After approximately two minutes the drain will be opened to gravity and two minutes of additional time will be allotted to drain any excess povidone iodine or ethanol. The catheter will then be removed, and the site dressed with gauze and film dressing. The patient will then be followed clinically in the hospital for at least 48 hours and by phone check in for 7 days.

Study Details

This is a single center, two arm phase I/II clinical trial exploring the use of chemical sclerosants (ethanol and povidone iodine) in decreasing the time needed for catheter drainage for patients with non-fistulous intraabdominal abscesses. The target study sample size is 60 patients, 30 in each arm and abscess size is to be a minimum of 3cm in all 3 dimensions. The primary outcomes of interest will be tolerability and need for catheter reinsertion by one week post intervention.

Key Dates

Start date

Jul 31, 2026

Status verified

Jul 2025

Primary completion

Jul 31, 2028

Completion

Jul 31, 2028

Study Design

Enrollment

60 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: Iodine Arm
  Catheter-based drainage and povidone iodine sclerotherapy of non-fistulous intraabdominal abscesses.
• Active Comparator: Ethanol Arm
  Catheter-based drainage and ethanol sclerotherapy of non-fistulous intraabdominal abscesses.

Primary Outcome Measure

Percentage of patients with VAS pain exceeding 7 following the catheter sclerotherapy or SIR grade 3 or higher complication. [ Time Frame: Baseline to day 7 plus or minus 7 days ]

Central Contacts

• Evan Husdon, MS
  205-934-6499
  [email protected]

Locations (1)

Find similar trials in Birmingham, AL

Related Studies

• Antibiotic Irrigations for Intra-Abdominal Drains
  PHASE2 · Recruiting · Paolo Goffredo · Iowa City, Iowa